LBTYA- Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies Inc.ITCI
$127.02Name : Intra-Cellular Therapies Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $13,495,112,704.00
EPSttm : -0.88
Intra-Cellular Therapies Inc.
$127.02
0.02%$0.02Float Short %
1.51
Margin Of Safety %
Put/Call OI Ratio
0.64
EPS Next Q Diff
0.11
EPS Last/This Y
0.78
EPS This/Next Y
0.86
Price
127.03
Target Price
127.45
Analyst Recom
2.29
Performance Q
67.55
Relative Volume
1.1
Beta
0.73
Ticker: ITCI
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-30 | ITCI | 83.51 | 0.37 | 0.02 | 5284 |
| 2024-12-31 | ITCI | 83.51 | 0.38 | 0.73 | 5245 |
| 2025-01-02 | ITCI | 84.23 | 0.37 | 0.02 | 5345 |
| 2025-01-03 | ITCI | 83.79 | 0.36 | 0.44 | 5459 |
| 2025-01-06 | ITCI | 81.69 | 0.36 | 0.23 | 5488 |
| 2025-01-07 | ITCI | 83.2 | 0.36 | 0.02 | 5561 |
| 2025-01-08 | ITCI | 82.52 | 0.36 | 0.50 | 5600 |
| 2025-01-09 | ITCI | 82.56 | 0.36 | 0.45 | 5600 |
| 2025-01-10 | ITCI | 94.91 | 0.36 | 1.31 | 5594 |
| 2025-01-13 | ITCI | 127.19 | 0.57 | 0.65 | 7001 |
| 2025-01-14 | ITCI | 126.82 | 0.65 | 0.82 | 16521 |
| 2025-01-15 | ITCI | 126.76 | 0.65 | 8.39 | 18694 |
| 2025-01-16 | ITCI | 126.26 | 0.82 | 1.98 | 20851 |
| 2025-01-17 | ITCI | 126.18 | 0.86 | 21.86 | 21418 |
| 2025-01-21 | ITCI | 126.51 | 1.97 | 2.74 | 15230 |
| 2025-01-22 | ITCI | 127.24 | 2.08 | 0.50 | 15997 |
| 2025-01-23 | ITCI | 127.08 | 1.55 | 1.77 | 22176 |
| 2025-01-24 | ITCI | 127.35 | 1.60 | 0.08 | 28407 |
| 2025-01-27 | ITCI | 127.25 | 0.78 | 2.41 | 42202 |
| 2025-01-28 | ITCI | 126.82 | 0.65 | 0.56 | 47548 |
| 2025-01-29 | ITCI | 127.03 | 0.64 | 0.24 | 48448 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-30 | ITCI | 83.46 | 65.3 | 165.6 | -0.68 |
| 2024-12-31 | ITCI | 83.51 | 65.3 | 166.4 | -0.68 |
| 2025-01-02 | ITCI | 84.22 | 65.3 | 166.9 | -0.68 |
| 2025-01-03 | ITCI | 83.72 | 65.3 | 166.1 | -0.68 |
| 2025-01-06 | ITCI | 81.71 | 65.3 | 165.2 | -0.68 |
| 2025-01-07 | ITCI | 83.26 | 65.3 | 167.3 | -0.68 |
| 2025-01-08 | ITCI | 82.56 | 65.3 | 166.0 | -0.68 |
| 2025-01-09 | ITCI | 82.56 | 65.3 | 166.4 | -0.68 |
| 2025-01-10 | ITCI | 94.90 | 65.3 | 174.0 | -0.68 |
| 2025-01-13 | ITCI | 127.15 | 65.3 | 183.3 | -0.68 |
| 2025-01-14 | ITCI | 126.85 | 65.3 | 166.3 | -0.68 |
| 2025-01-15 | ITCI | 126.71 | 65.3 | 166.4 | -0.68 |
| 2025-01-16 | ITCI | 126.27 | 65.3 | 166.3 | -0.68 |
| 2025-01-17 | ITCI | 126.17 | 65.0 | 166.4 | -0.68 |
| 2025-01-20 | ITCI | 126.20 | 65.0 | 166.4 | -0.68 |
| 2025-01-21 | ITCI | 126.50 | 65.0 | 166.5 | -0.68 |
| 2025-01-22 | ITCI | 127.24 | 65.0 | 166.7 | -0.68 |
| 2025-01-23 | ITCI | 127.07 | 65.0 | 166.4 | -0.68 |
| 2025-01-24 | ITCI | 127.35 | 65.0 | 166.5 | -0.68 |
| 2025-01-27 | ITCI | 127.22 | 65.0 | 166.4 | -0.68 |
| 2025-01-28 | ITCI | 127.00 | 65.1 | 166.3 | -0.68 |
| 2025-01-29 | ITCI | 127.03 | 65.0 | 166.4 | -0.68 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-30 | ITCI | -6.19 | -0.75 | 1.90 |
| 2024-12-31 | ITCI | -6.19 | -0.75 | 1.90 |
| 2025-01-02 | ITCI | -6.11 | -0.75 | 1.90 |
| 2025-01-03 | ITCI | -6.11 | -0.75 | 1.90 |
| 2025-01-06 | ITCI | -6.15 | -0.76 | 1.90 |
| 2025-01-07 | ITCI | -6.15 | -0.76 | 1.90 |
| 2025-01-08 | ITCI | -6.11 | -0.76 | 1.90 |
| 2025-01-09 | ITCI | -6.10 | -0.76 | 1.90 |
| 2025-01-10 | ITCI | -6.10 | -0.76 | 1.90 |
| 2025-01-13 | ITCI | -6.10 | -0.74 | 2.00 |
| 2025-01-14 | ITCI | -6.10 | -0.74 | 2.00 |
| 2025-01-15 | ITCI | -6.10 | -0.74 | 2.00 |
| 2025-01-16 | ITCI | -6.09 | -0.74 | 1.99 |
| 2025-01-17 | ITCI | -6.09 | -0.74 | 1.99 |
| 2025-01-20 | ITCI | -6.09 | -0.78 | 1.99 |
| 2025-01-21 | ITCI | -6.09 | -0.78 | 1.99 |
| 2025-01-22 | ITCI | -6.09 | -0.78 | 1.99 |
| 2025-01-23 | ITCI | -6.09 | -0.78 | 1.99 |
| 2025-01-24 | ITCI | -6.09 | -0.78 | 1.99 |
| 2025-01-27 | ITCI | -6.09 | -0.72 | 1.99 |
| 2025-01-28 | ITCI | -6.09 | -0.72 | 1.51 |
| 2025-01-29 | ITCI | -6.09 | -0.72 | 1.51 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.25
Avg. EPS Est. Current Quarter
-0.1
Avg. EPS Est. Next Quarter
-0.14
Insider Transactions
-6.09
Institutional Transactions
-0.72
Beta
0.73
Average Sales Estimate Current Quarter
194
Average Sales Estimate Next Quarter
198
Fair Value
Quality Score
48
Growth Score
41
Sentiment Score
93
Actual DrawDown %
0.8
Max Drawdown 5-Year %
-50.2
Target Price
127.45
P/E
Forward P/E
344.27
PEG
P/S
21.99
P/B
11.76
P/Free Cash Flow
EPS
-0.86
Average EPS Est. Cur. Y
-0.68
EPS Next Y. (Est.)
0.18
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-14.07
Relative Volume
1.1
Return on Equity vs Sector %
-26.6
Return on Equity vs Industry %
-16.2
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
166.4
Intra-Cellular Therapies Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 610
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
stock quote shares LBTYA- Intra-Cellular Therapies, Inc. Stock Price stock today
news today LBTYA- Intra-Cellular Therapies, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LBTYA- Intra-Cellular Therapies, Inc. yahoo finance google finance
stock history LBTYA- Intra-Cellular Therapies, Inc. invest stock market
stock prices ITCI premarket after hours
ticker ITCI fair value insiders trading